Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
205.78
-1.54 (-0.74%)
Official Closing Price
Updated: 7:00 PM EST, Dec 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
↗
January 02, 2025
The company said it plans to investigate a positive signal from female patients.
Via
Investor's Business Daily
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
January 02, 2025
From
Johnson & Johnson
Via
Business Wire
10 Stock Market Predictions for 2025
↗
January 01, 2025
Here's what to expect from the stock market, along with some of Wall Street's hottest trends and most influential businesses, in the new year.
Via
The Motley Fool
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
↗
December 31, 2024
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought.
Via
Benzinga
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
↗
December 13, 2024
Via
Benzinga
The Analyst Landscape: 15 Takes On Johnson & Johnson
↗
December 10, 2024
Via
Benzinga
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
↗
December 31, 2024
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall.
Via
Benzinga
Topics
Stocks
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
↗
December 31, 2024
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.
Via
Benzinga
5 Unbeatable Stocks I'm Eager to Buy in 2025
↗
December 30, 2024
These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.
Via
The Motley Fool
10 Dividend Stocks For Intergenerational Wealth
↗
December 27, 2024
The Dividend Aristocrats broadly have durable competitive advantages, and long-term growth.
Via
Talk Markets
Topics
Stocks / Equities
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
↗
December 27, 2024
Johnson & Johnson (NYSE:JNJ) enters bearish pattern, death cross, but strong dividends & strategic moves in dermatology provide long-term appeal.
Via
Benzinga
The Smartest Dividend Stocks to Buy With $1,000 Right Now
↗
December 26, 2024
Via
The Motley Fool
10 Buy And Hold Forever Dividend Stocks
↗
December 25, 2024
The following 10 stocks represent Dividend Kings that can continue to raise their dividends for decades to come.
Via
Talk Markets
Topics
Stocks / Equities
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
↗
December 25, 2024
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip...
Via
Benzinga
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
↗
December 24, 2024
Via
The Motley Fool
The Options Market Is Pointing Us At Four Dividend Stocks Right Now
↗
December 23, 2024
It’s a good idea to look at stocks that can give us what we need in the absence of a rally.
Via
Talk Markets
Topics
Bonds
Commodities
Stocks / Equities
5 Lowest Volatility Dividend Stocks
↗
December 20, 2024
Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
↗
December 19, 2024
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Via
Benzinga
The Smartest Dividend Stocks to Buy With $500 Right Now
↗
December 18, 2024
Via
The Motley Fool
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
↗
December 17, 2024
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy
Via
Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
↗
December 13, 2024
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Via
Benzinga
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 12, 2024
From
Johnson & Johnson
Via
Business Wire
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
↗
December 12, 2024
Via
The Motley Fool
Topics
Stocks
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
↗
December 12, 2024
When asked about Advanced Micro Devices, Cramer asks: "But can we just remember Lisa Su has built an amazing company?"
Via
Benzinga
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
↗
December 11, 2024
Jim Cramer expressed strong buying conviction for Netflix Inc. during Wednesday's Lightning Round on "Mad Money," as the streaming giant's shares traded near $934 amid broader tech market strength.
Via
Benzinga
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap
↗
December 11, 2024
Only 25 listed companies have a higher market capitalization than Elon Musk's skyrocketing net worth.
Via
Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
↗
December 10, 2024
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 10, 2024
Via
Benzinga
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
December 10, 2024
From
Johnson & Johnson
Via
Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
↗
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today